Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies

BACKGROUND: We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of disease activity-3 (NEDA-3) at 1 and 2 years, and to identify factors associated with failing to meet no evidence of disease activity 3 at 2 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Alonso, Ricardo, Casas, Magdalena, Lazaro, Luciana, Fernandez Liguori, Nora, Pita, Cecilia, Cohen, Leila, Rojas, Juan Ignacio, Pappolla, Agustín, Patrucco, Liliana, Cristiano, Edgardo, Burgos, Marcos, Vrech, Carlos, Piedrabuena, Raul, Pablo, Lopez, Deri, Norma, Luetic, Geraldine, Miguez, Jimena, Cabrera, Mariela, Martinez, Alejandra, Zanga, Gisela, Tkachuk, Verónica, Tizio, Santiago, Carnero Contentti, Edgar, Knorre, Eduardo, Leguizamon, Felisa, Mainella, Carolina, Nofal, Pedro, Liwacki, Susana, Hryb, Javier, Menichini, Maria, Pestchanker, Claudia, Alonso, Marina, Garcea, Orlando, Silva, Berenice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950613/
https://www.ncbi.nlm.nih.gov/pubmed/36846108
http://dx.doi.org/10.1177/20552173231154712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950613/
https://www.ncbi.nlm.nih.gov/pubmed/36846108
http://dx.doi.org/10.1177/20552173231154712

Ejemplares similares